The glycosyltransferases B4GALNT3 and B4GALT3 were mistakenly analyzed as B4GALNT3 in this review. The Table [1](#T1){ref-type="table"} was changed and the text in the last paragraph of "Glycosyltransferases as tumor markers in NB patients" was modified as follows.

###### 

**Glycosyltransferases as neuroblastoma (NB) tumor markers**.

  Enzyme                                                            Method/sample            Clinical significance                 Reference
  ----------------------------------------------------------------- ------------------------ ------------------------------------- ---------------------------------------
  β1,4-*N*-acetylgalactosaminyltransferase (GD2 synthase)           ICC/bone marrow          Molecular marker of metastatic NB     *J Clin Oncol*; 4:363--369 (1986)
                                                                    RT-PCR ECL/bone marrow   Molecular marker of metastatic NB     Cancer; 92:924--931 (2001)
                                                                    RT-PCR ECL/bone marrow   Molecular marker of metastatic NB     Am J Pathol; 159:493--500 (2001)
                                                                    qRT-PCR/bone marrow      Marker for minimal residual disease   J Clin Oncol; 21:1087--1093 (2003)
                                                                    qRT-PCR/bone marrow-PB   Prognostic marker (poor outcome)      Int J Cancer; 123:2849--2855 (2008)
  Sialyltransferase STX (ST8SiaII)                                  qRT-PCR/bone marrow      Molecular marker of metastatic NB     Int. Cancer; 119:152--156 (2006)
  *N*-acetylglucosaminyltransferase V (GnT-V)                       qRT-PCR/primary tumor    Prognostic marker (better outcome)    FEBS Lett; 580:627--632 (2006)
  UDP-polypeptide GalNAc-transferase 13 (GalNAc-T13 -- *GALNT13*)   RT-PCR/bone marrow       Molecular marker of metastatic NB     Clin Chem; 52:1701--1712 (2006)
  UDP-polypeptide GalNAc-transferase 9 (GalNAc-T9 -- *GALNT9*)      RT-PCR/primary tumor     Prognostic marker (better outcome)    Clin Chem; 59(1):225--233 (2013)
  β1,3-*N*-acetylglucosaminyltransferase-3 (*B3GNT3*)               IHC/primary tumor        Prognostic marker (better outcome)    Cancer Sci; 104:1600--1608 (2013)
  β1,4-*N*-acetylgalactosaminyltransferase 3 (*B4GALNT3*)           IHC/primary tumor        Prognostic marker (better outcome)    Am J Pathol; 179:1394--1404 (2011)
  β-1,4-galactosyltransferase III (*B4GALT3*)                       IHC/primary tumor        Prognostic marker (poor outcome)      Clin Cancer Res; 19:1705--1716 (2013)

*ICC, immunocytochemistry; RT-PCR, reverse transcriptase-polymerase chain reaction; ECL, electrochemiluminescence; PB, peripheral blood; IHC, immunohistochemistry*.

β1,4-*N*-acetylgalactosaminyltransferase III (*B4GALNT3*) cloned by Sato et al., has been described as expressed in stomach, colon, and testis (136). This enzyme can transfer GalNAc residues to non-reducing terminal GlcNAc-β leading to the synthesis of GalNAcβ1--4GlcNAc (also known as LacdiNAc or LDN), which is a unique terminal structure in the outer chain moieties of human *N*-glycans (137), and also in *O*-linked oligosaccharide structures (138). The largest amount of *B4GALNT3* transcripts were found in gastric tissues, followed by colon, testis, and adrenal glands (136). Gastric expression of *B4GALNT3* was found regulated by cellular differentiation (139). In the human colon, Huang et al. reported that *B4GALNT3* is up-regulated in primary tumors comparing with the normal mucosa (140). They performed *in vitro* and *in vivo* experiments showing that overexpression of this enzyme increases malignant phenotype of colon cancer cells, and these phenotypic changes are associated with enhanced integrin and mitogen-activated protein kinase (MAPK) signaling, suggesting that *B4GALNT3* may play a crucial role in promoting malignant behavior of colon cancer (140). The same research team has recently published that β-1,4-galactosyltransferase III (*B4GALT3*) overexpression in colorectal cancer cells suppressed cell migration, invasion, and adhesion, while *B4GALT3* knockdown enhanced malignant cell phenotypes promoting cell migration and invasion (141). Surprisingly, an opposite situation was found for both enzymes in NB. Firstly Hsu et al. communicated that *B4GALNT3* expression positively correlates with the differentiation status of NB, predicting a favorable prognosis for patients and suppressing the malignant phenotype in cell lines experiments via decreasing β1-integrin signaling (142). By contrast, β-1,4-galactosyltransferase III (*B4GALT3*) expression in NB tumors correlated with advanced clinical stage, unfavorable histology, and lower survival rate (143). In conclusion, *B4GALNT3* in NB seems a good prognostic marker, while *B4GALT3* was suggested as poor outcome marker. Further work is necessary to elucidate subjacent molecular mechanisms for these enzymes.
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